According to the Zhitong Finance App, Shiyao Group (01093.HK) announced that phase I clinical trials of the SYS6057 recombinant respiratory syncytial virus (RSV) vaccine (Chinese hamster ovary (CHO cells)) (this product) developed by the Group have officially started in China.

Zhitongcaijing · 1d ago
According to the Zhitong Finance App, Shiyao Group (01093.HK) announced that phase I clinical trials of the SYS6057 recombinant respiratory syncytial virus (RSV) vaccine (Chinese hamster ovary (CHO cells)) (this product) developed by the Group have officially started in China.